Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB-119 in Type 2 Diabetes Mellitus
NCT03072407Phase 1Completed
- Sponsor
- PegBio
- Start
- Nov 2015
- Primary completion
- Nov 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of visepegenatide in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by PegBio. Primary endpoint: Number of Adverse Events at 4 weeks. Started Nov 2015; status: completed.
02
Drugs
visepegenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03072407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072407.